Live Breaking News & Updates on Alpine Study Data

Stay updated with breaking news from Alpine study data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. ....

San Diego , United States , Jenniferr Brown , Extended Follow Up , Zanubrutinib Versus Ibrutinib , Refractory Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Partnership With , Alpine Study , Chronic Lymphocytic Leukemia , Btk Inhibitor , Cll Treatment , Alpine Trial , Alpine Study Data , Alpine Study Results , Alpine Extended Follow Up ,